Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791717 | 0.79 | CHRNA7 (0.77) | DRD4DRD2GRIN1GRIN2BHTT | |
| SCHEMBL4816882 | 0.79 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL31370749 | 0.79 | DRD4 (0.69) | DRD4DRD2GRIN1GRIN2BHTT | |
| SCHEMBL5157052 | 0.77 | HTT (0.84) | DRD4DRD2GRM2GRIN1GRIN2B | |
| SCHEMBL8436102 | 0.77 | GRIN1 (0.73) | DRD4DRD2GRIN1GRIN2BHTT | |
| SCHEMBL6194908 | 0.77 | MEN1 (0.64) | DRD4DRD2GRM2MEN1KMT2A | |
| SCHEMBL6941438 | 0.76 | HTT (0.69) | DRD4DRD2GRM2GRIN1GRIN2B | |
| SCHEMBL21798525 | 0.76 | CHRNA7 (0.71) | DRD4DRD2GRIN1GRIN2BHTT | |
| SCHEMBL18992217 | 0.76 | HTT (0.64) | DRD4DRD2GRIN1GRIN2BHTT | |
| SCHEMBL4805542 | 0.75 | DRD4 (1.00) | DRD4DRD2GRM2GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373220-B1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-05-30 | — | — | EP | claimed |
| US-7022728-B2 | Benzimidazoles that are useful in treating male sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-04-04 | — | — | US | claimed |
| EP-1483258-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | claimed |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-06-10 | — | — | US | claimed |
| EP-1373220-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003076431-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | claimed |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABOTT LABORATORIES | 2003-01-09 | — | — | US | claimed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | claimed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | claimed |
| US-7351828-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1373220-B1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7022728-B2 | Benzimidazoles that are useful in treating male sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-04-04 | — | — | US | disclosed |
| US-6960589-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2005-11-01 | — | — | US | disclosed |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABOTT LABORATORIES | 2003-01-09 | — | — | US | disclosed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885GRM2 3209/4885 |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885GRM2 3209/4885 |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885GRM2 3209/4885 |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885GRM2 3209/4885 |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885GRM2 3209/4885 |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885GRM2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.